购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Antibiotic
    (1)
  • Others
    (2)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (1)
  • 35日内发货
    (2)
  • 10-14周
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "pentylenetetrazole seizure mice"的结果
筛选
搜索结果
TargetMol产品目录中 "

pentylenetetrazole seizure mice

"的结果
  • 抑制剂&激动剂
    4
    TargetMol | Inhibitors_Agonists
  • 天然产物
    1
    TargetMol | Natural_Products
  • 同位素
    1
    TargetMol | Isotope_Products
  • Penicillamine
    青霉胺, D-penicillamine, Dimethyl Cysteine, D-(-)-Penicillamine, Artamine
    T098352-67-5
    Penicillamine (Artamine) 是一种 penicillin 的代谢降解产物,是一种螯合剂,可作用于威尔逊氏病。
    • ¥ 145
    In stock
    规格
    数量
    TargetMol | Inhibitor Hot
  • (R)-AS-1
    T2032602506367-95-7
    (R)-AS-1 是一种选择性激动性氨基酸转运体2 (EAAT2) 的正向异构调节剂,其EC50为11 nM。(R)-AS-1 以60和90 mg kg剂量显著增加小鼠的自发运动活动。在最大电休克 (MES)、戊四氮 (PTZ) 和电流刺激 (32或44 mA) 所引发的小鼠癫痫模型中,(R)-AS-1 显示出抗癫痫活性,ED50分别为66.3、36.3、15.6和41.6 mg kg。此化合物可应用于神经疾病的研究。
    • 待询
    10-14周
    规格
    数量
  • Zonisamide-13C2,15N
    Zonisamide-13C2,15N
    T378471188265-58-8
    Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg kg, respectively). Zonisamide (40 mg kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy. |1. Masuda, Y., Ishizaki, M., and Shimizu, M. Zonisamide: Pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 4(4), 341-360 (1998).|2. Rock, D.M., Macdonald, R.L., and Taylor, C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3(2), 138-143 (1989).|3. Suzuki, S., Kawakami, K., Nishimura, S., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12(1), 21-27 (1992).|4. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).|5. De Simone, G., Di Fiore, A., Menchise, V., et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15(9), 2315-2320 (2005).|6. Yabe, H., Choudhury, M.E., Kubo, M., et al. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 110(1), 64-68 (2009).
    • ¥ 6930
    35日内发货
    规格
    数量
  • 2-(Isopentylamino)naphthalene-1,4-dione
    T379501607447-79-9
    2-(Isopentylamino)naphthalene-1,4-dione is a vitamin K analog.1It inhibits spasms induced by pentylenetetrazole and tonic hindlimb extension induced by maximal electroshock (MES) in mice (ED50s = 349.2 and 108.1 mg/kg, respectively). It also protects mice against seizures in the 6 Hz psychomotor seizure test (ED50s = 152.7 and 263.7 mg/kg at stimulus intensities of 32 and 44 mA, respectively). 1.Li, X., Himes, R.A., Prosser, L.C., et al.Discovery of the first vitamin K analogue as a potential treatment of pharmacoresistant seizuresJ. Med. Chem.63(11)5865-5878(2020)
    • 待估
    35日内发货
    规格
    数量